Novo and Eli Lilly stocks could go higher if they show even better data than we think: Mizuho’s Holz

Jared Holz, Mizuho healthcare specialist, joins ‘Squawk on the Street’ to discuss what to expect from Novo Nordisk’s quarterly earnings results, if weight-loss drugs will get covered by insurance, and what’s moved Eli Lilly and Novo Nordisk’s stocks to this point and future growth prospects.